Silence Therapeutics Plc (SLNCF)
6.526
0.00 (0.00%)
USD |
OTCM |
Nov 18, 16:00
Silence Therapeutics Shareholders Equity (Quarterly) : 215.02M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 215.02M |
| June 30, 2026 | 38.47M |
| March 31, 2026 | 49.40M |
| December 31, 2025 | 62.30M |
| September 30, 2025 | 74.06M |
| June 30, 2025 | 94.16M |
| March 31, 2025 | 112.74M |
| September 30, 2024 | 126.78M |
| June 30, 2024 | 142.22M |
| Date | Value |
|---|---|
| March 31, 2024 | 156.52M |
| December 31, 2023 | 21.74M |
| September 30, 2023 | 24.41M |
| June 30, 2023 | 15.58M |
| March 31, 2023 | 20.51M |
| December 31, 2022 | 26.55M |
| September 30, 2022 | 38.10M |
| June 30, 2022 | -5.756M |
| March 31, 2022 | 5.253M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 25.98M |
| Mereo BioPharma Group Plc | 23.71M |
| Compass Pathways Plc | 142.07M |
| HemoGenyx Pharmaceuticals Plc | -- |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 281.50M |
| Total Liabilities (Quarterly) | 66.48M |
| Debt to Equity Ratio | 0.0004 |
| Current Ratio | 23.94 |
| Net Debt Paydown Yield | 0.00% |